Innate Pharma S.A. is a global, clinical-stage biotechnology company specializing in oncology-focused immunotherapies that harness the innate immune system to combat cancer. Founded in 1999 by pioneers in innate immunity, the company leverages expertise in natural killer cell biology and antibody engineering to develop innovative antibody therapeutics targeting high-unmet-need cancers. Its pipeline features lead assets like lacutamab, a first-in-class anti-KIR3DL2 antibody for Sézary syndrome, mycosis fungoides, and peripheral T-cell lymphomas, with EMA PRIME and FDA Fast Track designations; monalizumab, an anti-NKG2A antibody partnered with AstraZeneca for squamous cell carcinoma of the head and neck and solid tumors; and next-generation NK cell engagers such as IPH6101 in collaboration with Sanofi. Additional candidates include IPH4502 (Nectin-4 ADC), IPH5201 (anti-CD39), and IPH5301 (anti-CD73), addressing immunosuppressive tumor microenvironments. Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma advances scientific innovation through robust partnerships, aiming to deliver differentiated therapies that improve patient outcomes in immuno-oncology.